Kornimate/medical-research-clean huggingface dataset:
a study of ginsenoside h dripping pills for advanced non-small cell lung cancer (nsclc)

Conditions: Non-small Cell Lung Cancer (NSCLC)

Summary: ginsenoside h dripping pills is a kind of traditional chinese medicine(tcm), this study is being conducted to evaluate the efficacy and safety of ginsenoside h dripping pills in patients with advanced (stage ⅲb/ⅳ) non-small cell lung cancer (syndrome of qi-deficiency) and explore the optimal dosage


Eligibility criteria:
inclusion criteria: 1. pathologically or cytologically proven stage iiib/iv nsclc with a measurable lesions (including postoperative recurrence or metastasis) 2. the patients who can not be treated by surgical resection, conventional radiotherapy and chemotherapy or molecular targeted drugs treatment failure, not willing to accept, or intolerance to radiotherapy and chemotherapy or molecular targeted therapy. 3. the tcm syndrome diagnosis of qi-deficiency. 4. aged 18-75 years, both male and female. 5. ecog performance status 0-2. 6. expected to survive more than 3 months. 7. joined in the test voluntarily and signed the informed consent by gcp regulation. exclusion criteria: 1. liver and kidney damage(tbil、alt、ast is higher than the limit of normal value of 1.5 times, abnormal cr). 2. patients with significant cachexia. 3. untreated symptomatic brain metastases. 4 .allergic constitution, or for a variety of drug allergy. 5 .combined with severe cardiovascular, hepatic, renal disease , pregnancy or breast-feeding women, psychopath. 6. participated in other clinical trial within 3 months. 7. treated by chemotherapy, radiotherapy or targeted therapy within 4 weeks. 8. possible to be treated by chemotherapy, radiotherapy or targeted therapy during the study. 9. not fit for the clinical trial judged by the investigator.
symprove iii: health services research study for treatment of the moderate and severe acute exacerbations of chronic bronchitis (aecb)

Conditions: Chronic Bronchitis

Summary: in this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (aecb) were collected. there were two different cohorts which were compared (moxifloxacin and other antibiotics) concerning effectiveness and tolerance. it was a prospective study which was accomplished in 100 ambulatory practice offices.

the study design was slightly changed to adapt the target population. due to these changes the study was restarted on 8th december 2009.

Eligibility criteria:
inclusion criteria: * acute exacerbation of chronic bronchitis from anthonisen type i or ii * fev1 of \< 50 % * patient must be ensured in the statutory health insurance * further contraindications of the prescribed pharmaceutical products must be considered exclusion criteria: * patients who change from one cohort to the other

Keywords: disease exacerbation acute exacerbations of chronic bronchitis aecb avelox bronchitis
intramuscular lipid and insulin action:ethnic aspects

Conditions: Obesity

Summary: high levels of the hormone insulin are associated with risk for heart disease and diabetes, and may make it hard to lose weight. the types of food eaten may affect insulin levels. the purpose of this study is to determine if manipulation of dietary carbohydrate content improves insulin sensitivity (si), augments weight loss, and promotes weight loss maintenance in healthy adults.


Eligibility criteria:
inclusion criteria: overweight, age 21-50 years,women must be premenopausal, normal glucose tolerance, weight stable for at least 6 months with a weight change no greater than 5 lbs. exclusion criteria: exclusion criteria were type 1 or type 2 diabetes, polycystic ovarian disease, bmi \ 300 pounds, weight change \>5 pounds in last 6 months, regular exercise \>2 hours per week, pregnancy, currently breastfeeding, cholesterol medications, any disorders of glucose or lipid metabolism, use of medication that could affect body composition or glucose metabolism (including oral contraceptives and blood pressure medications), current use of tobacco, use of illegal drugs in last 6 months, history of hypoglycemic episodes, major food allergies or food dislikes, women with inconsistent or absence of monthly menstrual cycles, and a medical history that counter-indicated inclusion in the study.

Keywords: obesity diet carbohydrate insulin
evaluation of circulating tumor dna as a theranostic marker in the management of glioblastomas.

Conditions: Glioblastoma; Molecular Disease

Summary: glioblastomas (gbm) are rare tumors of poor prognosis and their treatment is based on surgery followed by radiochemotherapy. clinical and imaging evaluation is not always straightforward: the more or less complete surgery, the pseudo-progression after radiochemotherapy, the radionecrosis, the diagnosis of the relapse and the follow-up under anti-angiogenic can pose problems clinicians and radiologists. accessibility to a plasma tumor molecular marker would greatly facilitate the follow-up of these patients. it is now established for many cancers that circulating tumor dna (ctna) has the same molecular abnormalities as those identified in the primary tumor cells. numerous studies have shown the prognostic value and diagnosis of the exploration of cdna.


Eligibility criteria:
inclusion criteria: * patients with grade iv glial tumor (glioblastoma according to who criteria) for which an indication of surgical excision with radiochemotherapy was chosen at a specialized multidisciplinary meeting of neuro-oncology at the chu amiens-picardy. * patients should: * be able to be followed at the chu of amiens throughout their treatment, * be at least 18 years of age, * be informed (or trusted) of the conditions and objectives of the study, * having given their free and informed consent in writing, * have a life expectancy of more than 6 months, * be affiliated to a social security scheme. exclusion criteria: * patients with recurrent tumors. * patients supported for another histology. * medical, psychological or social conditions that do not allow for proper understanding of the procedures inherent in the study. * patients under tutelage, curatorship.

Keywords: biopsy
rifl (rigid and flexing laryngoscope) vs. fiberoptic bronchoscope

Conditions: Intubation; Difficult

Summary: we will conduct a randomized trial comparing the success rate and time to intubation using the rifl vs. the fiberoptic bronchoscope, as the latter is commonly held to be the gold standard of difficult airway devices. specifically, we wish to compare the of intubation between the two devices in patients with potentially difficult airways as defined by an oropharyngeal class 3-4, bmi greater than 35, or in patients with a history of difficult intubation using direct laryngoscopy.

patients who require general anesthesia with endotracheal intubation will be identified the night prior to their surgery based upon the examination documented in their preoperative history and physical. if their body mass index achieves a calculated score of 35 or greater or they have an oropharyngeal class 4 airway then they will qualify to participate. after written informed consent is obtained, the intubation method would be randomized as one of two groups: intubation via use of the fiberoptic bronchoscope or the rifl. the intubation attempt will be terminated if the spo2 \ 100sec. if terminated, the patient will be mask ventilated and the attending anesthesiologist would determine the subsequent technique that will be used for airway management.

Eligibility criteria:
inclusion criteria: patients with known or suspected difficult airways defined as: * patients with an oropharyngeal score of 3 or 4 * patients whose body mass index calculates greater to or equal to 35 exclusion criteria: * patients who necessitate an awake fiberoptic intubation or a rapid sequence intubation.
modeling mood course to detect markers of effective adaptive interventions

Conditions: Bipolar Disorder

Summary: the goal of this study is to learn how to engage individuals with bipolar disorder in long-term monitoring of daily patterns of mood, stress, sleep, circadian rhythm, and medical adherence. knowledge gained will be used to develop a mobile health platform for the translation of a psychosocial intervention for bipolar disorder into an effective adaptive intervention.

bipolar disorder is a chronic illness of profound shifts in mood ranging from mania to depression. bipolar disorder is successfully treated by combining medication with psychosocial therapy, but care can prove inadequate in practice. with gaps in coverage and medication, along with imprecise guidelines on when, where, and how to intervene, promising psychosocial therapies require adaptive strategies to better address the specific needs of individuals in a timely manner. to accomplish this, however, requires evidence-based practices for adapting a psychosocial therapy. the long-term goal of this study is to address this knowledge gap, by establishing a mobile health platform for translating a psychosocial therapy in bipolar disorder into an effective adaptive intervention. an important first step and the specific goal of this study is to answer the question of how to engage individuals with bipolar disorder in long-term monitoring of their daily patterns of mood, stress, sleep, circadian rhythm, and medical adherence. to answer this question, individuals with bipolar disorder will interact with a smart-phone application and activity tracker over six weeks. individuals will record their symptoms twice-daily with the smart-phone application while activity, sleep, and heart rate are recorded with their activity tracker. in addition, individuals will be interviewed on a weekly basis. the study focuses on testing three engagement strategies: using activity trackers rather than self-reports; reviewing recorded symptoms with another person on a weekly basis; and synthesizing a person's data into charts and graphs.

Eligibility criteria:
inclusion criteria: * individuals diagnosed with bipolar disorder * individuals with a smart-phone exclusion criteria: * none
association between fear of falling and spinal stiffness.

Conditions: Joint(S) Degeneration; Old Age; Atrophy; Fear of Injury

Summary: 1. / evaluation of the fear of falling using an fes-i questionnaire, distribution of subjects according to the score into 3 groups (16-19: little concerned by the fear of falling, 20-27 moderately concerned, 28-64 very concerned by fear of falling) 2. / evaluation of lumbar articular mobility by the schober index, coxofemoral by hip goniometry in flexion and extension (no evaluation of other amplitudes because lack of abduction / abduction / external and internal rotation of the hip remain functional in walking and the balance)

1. / evaluation of the fear of falling using an fes-i questionnaire, distribution of subjects according to the score into 3 groups (16-19: little concerned by the fear of falling, 20-27 moderately concerned, 28-64 very concerned by fear of falling) 2. / evaluation of lumbar articular mobility by the schober index, coxofemoral by hip goniometry in flexion and extension (no evaluation of other amplitudes because lack of abduction / abduction / external and internal rotation of the hip remain functional in walking and the balance)

Eligibility criteria:
inclusion criteria: * over 75 years old, * ability to understand and answer a questionnaire in french * ability to stand up * patient from the melun hospital (santé pole center + nursing home of the ghsif) * affiliated with a social security scheme exclusion criteria: * mental disorders, * lumbar surgery
effect of medicago sativa on oral glucose tolerance in healthy adults

Conditions: Glucose Tolerance

Summary: previous preclinical investigations have found that medicago sativa promotes the decrease of glucose concentrations. to evaluate the acute effect of medicago sativa administration on glucose tolerance, insulin secretion, and insulin sensitivity in healthy individuals.

a randomized, double-blind, placebo-controlled, two-period, cross-over clinical trail will be carrie out in 15 healthy, sedentary individuals of both genders, who meet the following inclusion criteria: 25 to 40 years of age, normal fasting plasma glucose (≤ 5.5 mm/l), blood pressure (\<130/90 mmhg), body mass index of 25 to 29.9 kg/m2, no taking any medication known to affect glucose tolerance, nondrinkers and nonsmokers. no pregnant, and lactation estate for female participants. they will be select from the same neighborhood and socioeconomic status. after a fasting blood sample patients will be assigned at random-order through a closed-envelope selection, to receive one of two possible sequences during which they received either single oral doses of medicago sativa or homologated placebo in 1,500 mg and were crossover with a difference of at least 7 days washout interval. thirty minutes after each intervention patients underwent a 75-g oral glucose tolerant test (ogtt). area under the curve of glucose and insulin, phases of insulin secretion, and insulin sensitivity will be calculate for each treatment period.

Eligibility criteria:
inclusion criteria: * fasting plasma glucose ≤99 mg/dl. * two hours postload plasma glucose (100 a 139 mg/dl). * body mass index: 25 -39.9 kg/m2. * body weight stable over the last 3 months. * women in follicular phase of the menstrual cycle (days 3 to 8 of the cycle) at the time of laboratory tests. * sedentary. * nonsmokers. * body weight unchanged upper to 5% for at least 3 moths before the study. exclusion criteria: * women in pregnancy and/or breastfeeding * physical or mental disability that makes it impossible to perform the intervention. * diagnosis of hypertension or heart failure. * untreated thyroid disease. * consumption of oral agents or other medications or supplements with proven properties that modify the behavior of glucose and lipids (oral hypoglycemic agents, insulin, lipid-lowering). * diagnosis of liver disease or elevation twice of the upper normal value of liver enzymes. * diagnosis of renal disease or creatinine \>1.5 mg/dl. * diagnosis of prediabetes: fasting plasma glucose ≥100 mg/dl and/or 2h-ogtt ≥140mg/dl and/or glycated hemoglobin a1c (a1c) between 5.7 - 6-4 %. * diagnosis of type 2 diabetes mellitus (t2dm): fasting glucose ≥ 126 mg / dl and/or 2h-ogtt ≥ 200 mg/dl . * total cholesterol ≥ 280 mg/dl. * triglycerides ≥ 300 mg/dl. * known allergy to calcined magnesia or medicago sativa.

Keywords: medicago sativa insulin secretion insulin sensitivity
a prospective trial of nasal mupirocin, hexachlorophene body wash, and systemic antibiotics for prevention of recurrent methicillin resistant staphylococcus aureus infections

Conditions: Methicillin Resistant Staphylococcus Aureus Skin Infections

Summary: this clinical trial tests the hypothesis that body decolonization of patients with recurrent community-associated (ca) mrsa infections will significantly reduce the likelihood of recurrent ca-mrsa infection.

staphylococcus aureus is a ubiquitous pathogen, and causes infections of the skin, lung, bloodstream, and other body parts. over the past decade,community-acquired methicillin resistant s. aureus (ca-mrsa) infections, which were previously extremely rare, are occurring commonly worldwide. ca-mrsa is the most common cause of skin infection in many locales in the u.s. ca-mrsa strains are notable for their ability to spread in closed settings and cause recurrent infections among healthy persons. management of recurrent ca-mrsa infection is challenging and optimal prevention strategies are undefined. many experts recommend topical agents that decontaminate the body and/or anterior nares. however, there are no data that quantify the efficacy and safety of this approach. we conducted a prospective non-comparative clinical trial to quantify the efficacy and safety of body decolonization regimens in the prevention of ca-mrsa infection from an infectious diseases private practice group in northern california. the study population comprised of persons suffering from recurrent ca-mrsa infection. for this clinical trial, all subjects will be given: nasal mupirocin (bactroban nasal, twice daily), topical 3% hexachlorophene body wash (phisohex, daily), and an oral anti-mrsa antibiotic. the choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior mrsa isolates in a given patient. patients were interviewed in person baseline and by phone at 2 weeks, 3 months, and 6 months using a standardized questionnaire. the baseline survey, based on a previously developed instrument used for an epidemiologic investigation of mrsa asked about mrsa risk factors and health-related quality of life. follow up surveys asked about adverse drug effects, especially gastrointestinal and dermatologic side effects (2 week visit only) and incident skin and mrsa infections.

Eligibility criteria:
inclusion criteria: recurrent mrsa infections and had greater than or equal to 2 mrsa infections in the 6 months prior to enrollment

Keywords: mrsa methicillin resistant staphylococcus aureus staphylococcus aureus skin infections body decolonization
humanistic care in healthcare workers in coronavirus disease 2019

Conditions: Coronavirus Disease 2019

Summary: as of february 17th, 2020, china has 76396 confirmed cases of coronavirus disease 2019 (covid-19), including 2348 deaths. the impact factors of clinical outcomes among hospitalized patients still need to be clarified. the healthcare workers faced greater mental and physical pressure under long-term, high-intensity, high-risk working conditions. investigators aim to evaluate the positive effect of humanistic care for healthcare workers participated in the treatment of covid-19.

as of february 17th, 2020, china has 76396 confirmed cases of coronavirus disease 2019 (covid-19), including 2348 deaths. as the national medical team sent to wuhan, the investigators proposed a psychological and physical rehabilitation based humanistic care regimen generated from experience in treating patients with covid-19. the healthcare workers faced greater mental and physical pressure under long-term, high-intensity, high-risk working conditions. the investigators want to apply this regimen to the healthcare workers who participated in the treatment of covid-19, to evaluate the positive effect of humanistic care on preventing depression and post-traumatic stress disorder.

Eligibility criteria:
inclusion criteria: * healthcare-personnel who are working for treating covid-19 * agree to informed consent exclusion criteria: * disagree to consent

Keywords: coronavirus disease 2019 humanistic care mental health post-traumatic stress disorder healthcare workers
acute transcranial direct current stimulation in patients with systemic autoimmune myopathies

Conditions: Myopathy; Neurologic Manifestations; ElectroPhys: Myopathy

Summary: systemic autoimmune myopathies are a heterogeneous group of rheumatic diseases that primarily affect the skeletal muscles. the transcranial direct current stimulation technique has been frequent, for example, in patients with ischemic stroke or for the optimization of muscular performance in athletes. however, to date, there are no studies evaluating this technique in patients with systemic autoimmune myopathies. therefore, the main objective of the present prospective, randomized, double-blind, placebo-controlled study is to evaluate the safety and efficacy of the application of acute transcranial current stimulation session in patients with systemic autoimmune myopathies.

currently, there are no studies evaluating the transcranial current stimulation technique in patients with systemic autoimmune myopathies. therefore, the main objective of the present prospective, randomized, double-blind, placebo-controlled study is to evaluate the safety and efficacy of the application of acute transcranial direct current stimulation session in patients with systemic autoimmune myopathies.

Eligibility criteria:
inclusion criteria: * classification criteria - eular/acr 2017 * classification critera - connors et al. * objective muscle limb weakness exclusion criteria: * neoplasia * using heart pacemarker * using visceral metalic clips * infections (hiv, htlv-1, hepatitis, etc) * pregnance * previous historical of convulsions or epilepsies
an open label trial of stribild for antiretroviral (arv)-naïve hiv-2 infected adults in dakar, senegal

Conditions: HIV-2 Infection

Summary: there is a critical need for safe and effective antiretroviral treatment (art) regimens for hiv-2 infection. this is especially true in west africa, where the vast majority of the 1-2 million individuals infected with hiv-2 live and were access to effective art for hiv-2 is limited. hiv-2 is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors (nnrti) and the fusion inhibitor enfuvirtide (t-20) and mutations conferring broad resistance to nucleoside/nucleotide reverse transcriptase inhibitors (nrti) are frequently observed in hiv-2 from patients receiving art. although antiretroviral protease inhibitors (pi) can be used effectively to treat hiv- 2, hiv-1 and hiv-2 also exhibit important differences in their susceptibilities with studies indicating that saquinavir (sqv), lopinavir (lpv), and darunavir (drv) are the only potent pi's against hiv-2 replication and cross-resistance is frequent. although an increasing body of evidence supports the potential utility of integrase inhibitors (ini) against hiv-2, there have been no clinical trials to assess their effectiveness and they are not routinely available in resource-limited settings. these limitations present major challenges to hiv-2 treatment, particularly in the areas in which it is most prevalent. this study is the 1st use of stribild (elvitegravir (evg), cobicistat (cobi), emtricitabine (ftc), tenofovir disoproxil fumarate (tdf)), an ini-based single tablet regimen, in hiv-2 infected adults in west africa. the investigators hypothesize stribild will be safe and effective as art for hiv-2 infection. the specific aims of this study are: aim 1: a pilot, open label, 48 week trial of stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) in 30 arv-naïve hiv-2 infected adults in dakar, senegal. aim 2: determination of genotypic and phenotypic hiv-2 antiretroviral resistance in individuals with virologic failure (hiv-2 plasma rna \>250 copies/ml) participating in the 48 week trial of stribild


Eligibility criteria:
inclusion criteria: * written informed consent * age \> 18 years old * hiv-2 infection (confirmed by determinetm \& immunocomb ii) * arv-naïve * cd4 count \< 750 cells/mm3 and/or who stage 3 or 4 disease * anticipate residing in dakar area for duration of study exclusion criteria: * pregnancy or breast feeding * hiv-1 or hiv-1/hiv-2 dual infection * known allergy or contraindication to elvitegravir, cobicistat, emtricitabine, or tenofovir df * active tuberculosis (stribild contraindicated with rifampin)

Keywords: hiv-2